BACKGROUND AND OBJECTIVES: Enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 homolog (SUZ12), the key component of polycomb repressive complex 2, are of great importance in human cancer pathogenesis. This study was designed to investigate the clinical and prognostic significances of EZH2, EED and SUZ12 in colorectal cancer (CRC) patients. METHODS: The expression of EZH2, EED and SUZ12 mRNA was evaluated in 82 primary CRC and paired non-cancerous mucosa samples by qRT-PCR. RESULTS: We found that overall EZH2, EED and SUZ12 mRNA expression in the CRC tissues was significantly increased than in the non-cancerous tissue (p < 0.05). Increased EZH2, EED and SUZ12 mRNA expression was directly correlated with primary tumor size, regional lymph node metastases, distant metastasis and AJCC stage. Furthermore, CRC patients with higher level of EED, SUZ12 or EZH2 showed a worse disease-free survival (DFS) (p < 0.01). In multivariate analysis, the increased EZH2 expression may be a risk factor for the patients' 3-year DFS (HR 2.517; 95% CI 1.104, 5.736; p = 0.028). Furthermore, the k-means cluster analysis showed that high mRNA expression of EED, SUZ12 and EZH2 was significantly correlated with the aggressive clinical behavior and poor prognosis. CONCLUSIONS: High expression of EED, SUZ12 and EZH2 might contribute to the CRC development/progression.
BACKGROUND AND OBJECTIVES: Enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 homolog (SUZ12), the key component of polycomb repressive complex 2, are of great importance in humancancer pathogenesis. This study was designed to investigate the clinical and prognostic significances of EZH2, EED and SUZ12 in colorectal cancer (CRC) patients. METHODS: The expression of EZH2, EED and SUZ12 mRNA was evaluated in 82 primary CRC and paired non-cancerous mucosa samples by qRT-PCR. RESULTS: We found that overall EZH2, EED and SUZ12 mRNA expression in the CRC tissues was significantly increased than in the non-cancerous tissue (p < 0.05). Increased EZH2, EED and SUZ12 mRNA expression was directly correlated with primary tumor size, regional lymph node metastases, distant metastasis and AJCC stage. Furthermore, CRC patients with higher level of EED, SUZ12 or EZH2 showed a worse disease-free survival (DFS) (p < 0.01). In multivariate analysis, the increased EZH2 expression may be a risk factor for the patients' 3-year DFS (HR 2.517; 95% CI 1.104, 5.736; p = 0.028). Furthermore, the k-means cluster analysis showed that high mRNA expression of EED, SUZ12 and EZH2 was significantly correlated with the aggressive clinical behavior and poor prognosis. CONCLUSIONS: High expression of EED, SUZ12 and EZH2 might contribute to the CRC development/progression.
Authors: Tineke Wolters; Kees J Vissers; Chris H Bangma; Fritz H Schröder; Geert J L H van Leenders Journal: BJU Int Date: 2009-11-03 Impact factor: 5.588
Authors: Alexandra M Pietersen; Hugo M Horlings; Michael Hauptmann; Anita Langerød; Abderrahim Ajouaou; Paulien Cornelissen-Steijger; Lodewijk F Wessels; Jos Jonkers; Marc J van de Vijver; Maarten van Lohuizen Journal: Breast Cancer Res Date: 2008-12-19 Impact factor: 6.466
Authors: Frances Potjewyd; Anne-Marie W Turner; Joshua Beri; Justin M Rectenwald; Jacqueline L Norris-Drouin; Stephanie H Cholensky; David M Margolis; Kenneth H Pearce; Laura E Herring; Lindsey I James Journal: Cell Chem Biol Date: 2019-12-09 Impact factor: 8.116
Authors: Sónia Carvalho; Micaela Freitas; Luís Antunes; Sara Monteiro-Reis; Marcia Vieira-Coimbra; Ana Tavares; Sofia Paulino; José Flávio Videira; Carmen Jerónimo; Rui Henrique Journal: J Cancer Res Clin Oncol Date: 2018-08-13 Impact factor: 4.553